

Caroline Aspod

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4779545/publications.pdf>

Version: 2024-02-01

43
papers

2,341
citations

304743

22
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

3632
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell subsets in health and disease. <i>Immunological Reviews</i> , 2007, 219, 118-142.	6.0	370
2	Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. <i>Journal of Experimental Medicine</i> , 2007, 204, 1037-1047.	8.5	296
3	Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. <i>Journal of Experimental Medicine</i> , 2011, 208, 479-490.	8.5	233
4	X-Chromosome Complement and Estrogen Receptor Signaling Independently Contribute to the Enhanced TLR7-Mediated IFN- γ Production of Plasmacytoid Dendritic Cells from Women. <i>Journal of Immunology</i> , 2014, 193, 5444-5452.	0.8	176
5	Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL. <i>Cancer Immunology Research</i> , 2013, 1, 402-415.	3.4	146
6	Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection. <i>Gastroenterology</i> , 2012, 143, 1586-1596.e8.	1.3	115
7	Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1646-1656.	0.7	86
8	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	3.7	73
9	Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2551-2561.	0.7	65
10	Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. <i>Clinical and Experimental Immunology</i> , 2002, 130, 204-211.	2.6	56
11	Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. <i>European Journal of Dermatology</i> , 2010, 20, 016-023.	0.6	54
12	Immunotherapy Via Dendritic Cells. , 2005, 560, 105-114.		47
13	A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2010, 5, e10458.	2.5	47
14	Co-delivery of the NKT agonist α -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. <i>Oncolmmunology</i> , 2017, 6, e1339855.	4.6	45
15	T-Cell Homing to the Pancreas in Autoimmune Mouse Models of Diabetes: In Vivo MR Imaging. <i>Radiology</i> , 2005, 236, 579-587.	7.3	44
16	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00058.	2.5	38
17	An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. <i>Oncolmmunology</i> , 2020, 9, 1738812.	4.6	38
18	HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2395-2406.	0.7	37

#	ARTICLE	IF	CITATIONS
19	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. <i>Hepatology</i> , 2012, 56, 1706-1718.	7.3	34
20	Early events in islets and pancreatic lymph nodes in autoimmune diabetes. <i>Journal of Autoimmunity</i> , 2004, 23, 27-35.	6.5	33
21	The features of circulating and tumor-infiltrating $\hat{I}^3\hat{I}$ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome. <i>Oncolmmunology</i> , 2019, 8, 1601483.	4.6	32
22	Melanoma hijacks plasmacytoid dendritic cells to promote its own progression. <i>Oncolmmunology</i> , 2014, 3, e27402.	4.6	28
23	Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. <i>Scientific Reports</i> , 2016, 6, 30405.	3.3	25
24	Pegylated Interferon $\hat{I}\pm$ -2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. <i>PLoS ONE</i> , 2016, 11, e0158297.	2.5	22
25	Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2019, 10, 112.	4.8	22
26	Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. <i>Molecular Therapy</i> , 2017, 25, 534-546.	8.2	18
27	Tâ€cell receptor diversity as a prognostic biomarker in melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 612-624.	3.3	18
28	A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy. <i>Molecular Therapy</i> , 2013, 21, 1076-1086.	8.2	17
29	Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and $\hat{I}^3\hat{I}$ T Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints. <i>Frontiers in Immunology</i> , 2020, 11, 861.	4.8	17
30	pDCs efficiently process synthetic long peptides to induce functional virusâ€and tumourâ€specific Tâ€cell responses. <i>European Journal of Immunology</i> , 2014, 44, 2880-2892.	2.9	16
31	BDCA1⁺ cDC2s, BDCA2⁺ pDCs and BDCA3⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2020, 9, e1190.	3.8	16
32	$\hat{I}\pm$ 4 Integrins and L-selectin Differently Orchestrate T-cell Activity During Diabetes Prevention Following Oral Administration of CTB-insulin. <i>Journal of Autoimmunity</i> , 2002, 19, 223-232.	6.5	15
33	Paramagnetic nanoparticles to track and quantify in vivo immune human therapeutic cells. <i>Nanoscale</i> , 2013, 5, 11409.	5.6	12
34	Upregulation of Adhesion Molecules on Leukemia Targets Improves the Efficacy of Cytotoxic T Cells Transduced With Chimeric Anti-CD19 Receptor. <i>Journal of Immunotherapy</i> , 2013, 36, 181-189.	2.4	11
35	Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-9.	3.0	8
36	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and $\hat{I}^3\hat{I}$ T cells in melanoma patients, which impacts clinical outcomes. <i>Clinical and Translational Immunology</i> , 2021, 10, e1329.	3.8	7

#	ARTICLE	IF	CITATIONS
37	Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80 ⁺ PDL1 ⁺) pDC subset negatively correlated with clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2022, 11, e1382.	3.8	6
38	Humanized mice for the development and testing of human vaccines. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 949-960.	5.0	5
39	Reply to Comment on Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> 2019, 11, 1554. <i>Cancers</i> , 2020, 12, 2673.	3.7	4
40	The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94.	3.3	3
41	Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs. <i>Clinical and Translational Immunology</i> , 2020, 9, e1208.	3.8	3
42	Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment. <i>Cancer Research Communications</i> , 2022, 2, 577-589.	1.7	3
43	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0